检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study

Radhakrishnan Ramchandren,Peter Johnson,Nilanjan Ghosh,Jia Ruan,Kirit M. Ardeshna,Roderick Johnson,Gregor Verhoef,David Cunningham,Sven de Vos,Shireen Kassam,Luis Fayad,John Radford,Sarah Bailly,Fritz Offner, David Morgan,Javier Munoz,Jerry Ping,Edith Szafer-Glusman,Karl Eckert,Jutta K. Neuenburg

eClinicalMedicine（2023）

引用 5|浏览41
暂无评分
摘要
Pharmacyclics LLC, an AbbVie Company.
更多
查看译文
关键词
Diffuse large B-cell lymphoma,Ibrutinib,Lenalidomide,Rituximab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要